title: Expression changes and regulation of AR and IGF-1 in PC3 prostate cancer cells treated with sexual hormones and flutamide.
abstract: The study aims to investigate the changes and regulation of androgen receptor and insulin-like growth factor-1 in the PC3 prostate cells treated with 5α-dihydrotestosterone, estrone, and flutamide. The PC3 cells were cultured and treated with 5α-dihydrotestosterone, estrone, and flutamide. Immunocytochemistry and Western blot were used to detect the expression of androgen receptor and insulin-like growth factor-1. The androgen receptor expression was analyzed by Western blot and optic density scan in the presence or absence of various kinase inhibitors. The statistical calculations were performed with the statistics-analyzing software package SPSS 13.0. A P <0.05 was considered statistically significant. The concentrations of 5α-dihydrotestosterone and flutamide could almost not change the expression of androgen receptor and insulin-like growth factor-1 in PC3. But, the concentrations of estrone could increase the expression of androgen receptor and insulin-like growth factor-1 when PC3 cells are exposed to the studied concentration at various times. The expression of androgen receptor was regulated by the inhibitor of signal pathways of PI3, MEK1/2, and JUK. The expressions of androgen receptor and insulin-like growth factor-1 were influenced by estrone and were not influenced by 5α-dihydrotestosterone and flutamide in PC3 cells. And, the expression of androgen receptor was regulated by multiple signal pathways.
authors.affiliation: Department of Forensic Medicine, Zhongshan School of Medicine, Sun Yat-sen University, Zhongshan II road 74#, Guangzhou, 510080, China, tongdy@mail.sysu.edu.cn.
authors.forename: Da Yue
authors.initials: da Y
authors.lastname: Tong
authors.forename: Xin yao
authors.initials: Xy
authors.lastname: Wu
authors.forename: Hong yu
authors.initials: Hy
authors.lastname: Sun
authors.forename: Yi
authors.initials: Y
authors.lastname: Jin
authors.forename: Zhuo wei
authors.initials: Zw
authors.lastname: Liu
authors.forename: Fang jian
authors.initials: Fj
authors.lastname: Zhou
mesh_terms: D000726:Androgen Antagonists / Q000494:pharmacology; D000728:Androgens / Q000494:pharmacology; D015153:Blotting, Western; D013196:Dihydrotestosterone / Q000494:pharmacology*; D004967:Estrogens / Q000494:pharmacology; D004970:Estrone / Q000494:pharmacology*; D005485:Flutamide / Q000494:pharmacology*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D007124:Immunoenzyme Techniques; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011944:Receptors, Androgen / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D014407:Tumor Cells, Cultured
chemical_list: C410798:AR protein, human; D000726:Androgen Antagonists; D000728:Androgens; D004967:Estrogens; D047428:Protein Kinase Inhibitors; D011944:Receptors, Androgen; D013196:Dihydrotestosterone; D004970:Estrone; D007334:Insulin-Like Growth Factor I; D005485:Flutamide